1 hour ago
HomeMarket NewsStocks NewsRossari Biotech Q4 profit rises 33% on higher revenue, steady margins; declares 25% dividend
The company announced a final dividend of 25% (₹0.50 per equity share of face value ₹2) for FY26, subject to shareholder approval. Shares of Rossari Biotech Ltd ended at ₹506.15, down by ₹10.05, or 1.95%, on the BSE today, Monday 27.
2 Min Read
Specialty chemical company Rossari Biotech Ltd, on Monday (April 27), reported a 33.43% year-on-year rise in net profit to ₹46 crore for the fourth quarter, compared with ₹34 crore in the same period last year.
Revenue for Q4FY26 grew 18.2% to ₹684.8 crore from ₹579.5 crore in the corresponding quarter of the previous year. Earnings before interest, tax, depreciation and amortisation (EBITDA) increased 11% year-on-year to ₹77.2 crore from ₹69.5 crore. The EBITDA margin remained flat at 12% year-on-year.
The company announced a final dividend of 25% (₹0.50 per equity share of face value ₹2) for FY26, subject to shareholder approval. The dividend will be paid or dispatched within 10 working days from the conclusion of the ensuing annual general meeting, with the record date to be intimated separately.
ALSO READ | Rossari Biotech promoters exploring a stake sale amidst early stage interest: Exclusive
The company said its capacity expansion plan is being re-evaluated in view of evolving business requirements and market conditions. The proposed investment will now be implemented in a phased manner over the next two years, while the overall strategic intent of the expansion remains unchanged.
Rossari Biotech has also set up a new research and development facility at Navi Mumbai. The company will also relocate and shift its existing R&D facility from IIT Bombay to the new Navi Mumbai site. The new R&D facility forms part of its capital expenditure plan aimed at strengthening innovation, product development, and technological capabilities.
Separately, the company appointed Udeypaul Singh Gill as an additional director in the category of non-executive independent director for a three-year term from April 28, 2026, to April 27, 2029, subject to shareholder approval, based on the recommendation of the Nomination and Remuneration Committee.
ALSO READ | Rossari Biotech sees exports rising, plans to exit low-margin businesses
Shares of Rossari Biotech Ltd ended at ₹506.15, down by ₹10.05, or 1.95%, on the BSE today, April 27.
(Edited by : Shoma Bhattacharjee)
